Suppliers and packagers for erythromycin

erythromycin

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Pharmobedient	ERYTHROMYCIN	erythromycin	CAPSULE, DELAYED REL PELLETS;ORAL	062746	ANDA	Arbor Pharmaceuticals, Inc.	24338-120-13	100 CAPSULE, DELAYED RELEASE in 1 BOTTLE (24338-120-13)	2012-01-10
Padagis Us	ERYTHROMYCIN	erythromycin	GEL;TOPICAL	063211	ANDA	Padagis Israel Pharmaceuticals Ltd	45802-966-94	1 TUBE in 1 CARTON (45802-966-94) / 30 g in 1 TUBE	2008-06-12
Padagis Us	ERYTHROMYCIN	erythromycin	GEL;TOPICAL	063211	ANDA	Padagis Israel Pharmaceuticals Ltd	45802-966-96	1 TUBE in 1 CARTON (45802-966-96) / 60 g in 1 TUBE	2008-06-12
Padagis Us	ERYTHROMYCIN	erythromycin	GEL;TOPICAL	063211	ANDA	Bryant Ranch Prepack	63629-8652-1	1 TUBE in 1 CARTON (63629-8652-1) / 30 g in 1 TUBE	2008-06-12

Erythromycin Pharmaceutical Suppliers

Last updated: February 19, 2026

Erythromycin, a macrolide antibiotic, is manufactured by a limited number of global suppliers. Production is concentrated in Asia, primarily China and India, with a smaller presence in Europe. Key suppliers operate under stringent regulatory oversight from bodies including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The market is characterized by a reliance on a few dominant manufacturers for active pharmaceutical ingredient (API) and finished dosage forms.

Who are the primary global suppliers of erythromycin API?

The primary global suppliers of erythromycin active pharmaceutical ingredient (API) are concentrated in Asia. China and India dominate the manufacturing landscape. European suppliers exist but represent a smaller market share.

• China: Leads in API production volume. Companies include Zhejiang Medicine Co., Ltd., and Shijiazhuang Dongbang Pharmaceutical Co., Ltd. These entities often produce both the base erythromycin and its various salts and esters.
• India: Another significant producer. Companies such as Lupin Ltd. and Aarti Industries Limited are active in erythromycin API manufacturing. Their production capabilities cater to both domestic and international markets.
• Europe: A limited number of European manufacturers, such as Sanofi (formerly through legacy operations) and some smaller specialized chemical manufacturers, also produce erythromycin API. Their operations often focus on specific grades or niche markets.

The global supply chain for erythromycin API is influenced by regulatory compliance, cost of production, and raw material availability. Manufacturers must adhere to Good Manufacturing Practices (GMP) standards.

What are the main erythromycin finished dosage form (FDF) manufacturers?

Manufacturers of erythromycin finished dosage forms (FDFs) are more geographically diverse than API producers, though a significant portion still operates in Asia. These companies formulate the API into various dosage forms for patient use.

• Asia:
  • China: Companies like Shanghai Pharmaceuticals Holding Co., Ltd. and Jiangsu Hengrui Medicine Co., Ltd. manufacture a range of erythromycin products including tablets, capsules, and suspensions.
  • India: Manufacturers such as Cipla Ltd., Dr. Reddy's Laboratories, and Sun Pharmaceutical Industries Ltd. are key players. They produce a wide spectrum of oral and topical erythromycin formulations.
• Europe:
  • Germany: Companies like Bayer AG and Sanofi (through its European operations) have historically manufactured erythromycin FDFs.
  • United Kingdom: Smaller pharmaceutical firms may also be involved in specific product lines.
• North America:
  • United States: While domestic API production is limited, several pharmaceutical companies formulate and market erythromycin products, often sourcing API from international suppliers. Abbott Laboratories and Pfizer Inc. have been historically involved.

The choice of FDF manufacturer is often dictated by the specific market, regulatory approvals, and distribution networks.

What are the regulatory requirements for erythromycin suppliers?

Suppliers of erythromycin, both API and FDF, must comply with rigorous regulatory standards. These requirements ensure product quality, safety, and efficacy. Key regulatory bodies include:

• U.S. Food and Drug Administration (FDA): Requires adherence to Current Good Manufacturing Practices (CGMP). Facilities are subject to FDA inspection. Drug Master Files (DMFs) are often submitted for APIs.
• European Medicines Agency (EMA): Oversees the EU market. Requires Marketing Authorisation Applications (MAAs) for FDFs and certificates of suitability to the European Pharmacopoeia (CEP) for APIs. Inspections are conducted by national competent authorities within member states.
• Other National Regulatory Authorities: Agencies in Japan (PMDA), Canada (Health Canada), Australia (TGA), and other countries have their own specific requirements and inspection protocols.
• Pharmacopoeial Standards: Suppliers must meet the standards set by major pharmacopoeias, including the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). These standards define purity, assay, and other quality attributes.

Compliance involves detailed documentation, process validation, quality control testing, and ongoing monitoring.

What are the typical production capacities and scale for major erythromycin suppliers?

Major erythromycin suppliers possess significant production capacities, reflecting the drug's widespread use and historical importance. Exact figures are proprietary, but industry estimates indicate:

• API Production: Leading Chinese and Indian manufacturers can each produce hundreds to thousands of metric tons of erythromycin API annually. This scale is necessary to meet global demand.
• FDF Production: For finished dosage forms, capacities vary widely based on the specific product (e.g., tablets vs. suspensions) and the manufacturer's specialization. Large-scale FDF manufacturers can produce hundreds of millions of units (tablets, capsules, vials) per year.

Production scale is often supported by multi-site manufacturing facilities. These suppliers invest in advanced synthesis technologies and quality assurance systems to maintain large-scale, consistent output.

What are the key quality control parameters for erythromycin?

Key quality control parameters for erythromycin are critical for ensuring therapeutic effectiveness and patient safety. These are defined by pharmacopoeial monographs and regulatory guidelines.

• Assay: The quantitative determination of the erythromycin content. Typically must be within a narrow range (e.g., 90.0% to 102.0% on an anhydrous basis, depending on the specific form and pharmacopoeia).
• Related Substances/Impurities: Identification and quantification of process-related impurities and degradation products. Limits are set for individual known impurities, unknown impurities, and total impurities. Common impurities include erythromycin B, C, D, and process intermediates.
• Loss on Drying/Water Content: Measures the amount of volatile matter (primarily water) present. Crucial for stability and accurate dosing.
• Residue on Ignition/Sulphated Ash: Indicates the level of inorganic impurities.
• Heavy Metals: Limits for heavy metal contamination (e.g., lead, mercury).
• Chirality/Optical Rotation: For certain erythromycin forms, optical activity is a critical specification.
• Microbial Limits: For FDFs, especially oral suspensions, testing for absence of objectionable microorganisms and limits for total aerobic microbial count and yeast/mold count are essential.
• Uniformity of Dosage Units: For FDFs, ensures consistent API content across individual dosage units.

Suppliers must implement robust analytical methods, such as High-Performance Liquid Chromatography (HPLC) and Gas Chromatography (GC), to monitor these parameters.

How do erythromycin suppliers manage supply chain risks?

Erythromycin suppliers manage supply chain risks through a combination of strategies to ensure consistent production and delivery.

• Diversification of Raw Material Sources: Manufacturers often source key starting materials and intermediates from multiple approved suppliers to mitigate the risk of single-source dependency.
• Inventory Management: Maintaining strategic levels of raw materials, intermediates, and finished API allows for buffer against short-term disruptions.
• Regulatory Compliance and Auditing: Rigorous adherence to GMP and regular auditing of both in-house facilities and critical suppliers ensures quality and reduces the risk of product recalls or regulatory non-compliance.
• Geographic Diversification: While manufacturing is concentrated, some larger companies may have multiple production sites in different regions, offering redundancy.
• Long-Term Supplier Agreements: Establishing stable, long-term relationships with key suppliers fosters collaboration and ensures preferential treatment during periods of high demand or scarcity.
• Contingency Planning: Developing plans for alternative production methods, emergency sourcing, and logistics management in the event of unforeseen events (e.g., natural disasters, political instability, pandemics).
• Quality Agreements: Formal agreements with API and FDF customers define quality standards, responsibilities, and communication protocols, which are crucial for risk mitigation.

What is the market landscape and competitive intensity for erythromycin?

The market for erythromycin is mature, with established suppliers and a degree of commoditization, particularly for the API.

• Competition: High among API manufacturers, especially those in China and India, driven by cost efficiency and production volume. Competition for FDFs is also significant, with numerous generic manufacturers in various markets.
• Market Drivers: Demand is sustained by erythromycin's continued use as a cost-effective antibiotic for specific infections and its role in combination therapies or for patients with penicillin allergies.
• Barriers to Entry: Significant for new API manufacturers due to the capital investment required for GMP-compliant facilities, regulatory hurdles (DMF submissions, inspections), and the need to establish a track record of quality and reliability. For FDFs, regulatory approvals and distribution network establishment are key barriers.
• Pricing: API prices can be competitive, influenced by raw material costs, energy prices, and global supply-demand dynamics. FDF pricing is generally lower due to the presence of generic competition.
• Market Trends: A subtle shift towards higher-purity grades and greater emphasis on supply chain transparency and sustainability from pharmaceutical companies procuring erythromycin.

What are the primary synthesis routes for erythromycin?

Erythromycin is a natural product, produced via fermentation by the bacterium Saccharopolyspora erythraea (formerly Streptomyces erythreus). The synthesis of the core macrolide ring and its functionalization occurs within the microorganism.

The primary "synthesis route" therefore refers to the industrial fermentation and subsequent isolation and purification process.

1. Fermentation:

   • Saccharopolyspora erythraea is cultivated in large fermenters under controlled conditions (temperature, pH, aeration, nutrient supply).
   • The microorganism produces erythromycin A, B, and C as primary metabolites, with erythromycin A being the most abundant and therapeutically significant.
   • Media composition and strain improvement (through genetic engineering or classical mutagenesis) are optimized to maximize erythromycin yield.

2. Isolation and Purification:

   • After fermentation, the broth is processed to extract erythromycin. This typically involves:
     • Filtration/Centrifugation: To separate biomass from the liquid broth.
     • Extraction: Erythromycin is extracted from the broth using organic solvents (e.g., butyl acetate, methyl isobutyl ketone). pH adjustments are critical for efficient extraction.
     • Purification: Multiple steps are employed, including:
       • Acid-base extraction: To selectively isolate the basic erythromycin from neutral or acidic impurities.
       • Crystallization: From suitable solvent systems to achieve high purity.
       • Chromatography: Sometimes used for further purification or removal of specific impurities.
   • Drying of the purified erythromycin product to meet specified moisture content.

Chemical modifications of erythromycin are then performed to produce semi-synthetic derivatives like azithromycin and clarithromycin, which have improved pharmacokinetic properties and spectrum of activity. These modifications involve specific chemical reactions to alter functional groups on the erythromycin A molecule.

Key Takeaways

Erythromycin API production is dominated by a few large-scale manufacturers in China and India. Finished dosage form (FDF) manufacturing is more distributed globally but also features significant Asian and European players. All suppliers must adhere to stringent regulatory standards enforced by agencies like the FDA and EMA, with pharmacopoeial compliance being mandatory. Production capacities for API are measured in hundreds to thousands of metric tons annually, while FDF capacities are in the millions of units. Quality control focuses on assay, impurity profiling, and physical characteristics. Supply chain risk management involves raw material diversification, inventory control, regulatory adherence, and contingency planning. The market is mature and competitive, with pricing influenced by production costs and generic availability. Erythromycin is primarily produced through fermentation by Saccharopolyspora erythraea, followed by extensive isolation and purification processes.

FAQs

1. What is the primary chemical form of erythromycin supplied globally? The primary chemical form supplied globally is erythromycin A. While fermentation can yield erythromycin B and C, erythromycin A is the most potent and widely used for therapeutic purposes. Semi-synthetic derivatives like azithromycin and clarithromycin are also significant but are distinct compounds derived from erythromycin A.

2. Are there any significant North American or European-based API manufacturers for erythromycin currently active? While historically there may have been more, the significant global production of erythromycin API is now largely concentrated in Asia. A few European companies may produce specialized grades or operate in niche segments, but large-scale API manufacturing is predominantly based in China and India. North American API production for erythromycin is minimal.

3. What are the main challenges in maintaining a stable erythromycin supply chain? Challenges include reliance on a limited number of large API manufacturers, potential for raw material price volatility (especially for fermentation media components), geopolitical factors affecting international trade, and the need for continuous investment in regulatory compliance and facility upgrades. Public health crises can also strain supply.

4. How does the regulatory status of a supplier (e.g., FDA inspection history) impact their competitiveness? A strong regulatory history, demonstrated by successful FDA inspections and a lack of significant warning letters or import alerts, is crucial for competitiveness, particularly for suppliers targeting markets like the United States and Europe. Non-compliance can lead to product rejection, market access denial, and reputational damage, severely impacting a supplier's ability to secure contracts.

5. Can a pharmaceutical company easily switch between erythromycin API suppliers? Switching API suppliers is a complex process. It requires extensive due diligence, including auditing the new supplier's facilities and quality systems. Furthermore, regulatory filings (e.g., amendments to DMFs, variations in Marketing Authorisation Applications) must be submitted and approved by health authorities before a new API source can be used in the finished drug product. This process can take many months to over a year.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) for Drugs. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/current-good-manufacturing-practice-cgmp-drugs [2] European Medicines Agency. (n.d.). Scientific advice and protocols. Retrieved from https://www.ema.europa.eu/en/scientific-advice-protocols [3] United States Pharmacopeia. (n.d.). United States Pharmacopeia and National Formulary (USP-NF). Retrieved from https://www.usp.org/products/usp-nf [4] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability to the European Pharmacopoeia (CEP). Retrieved from https://www.edqm.eu/en/certificate-suitability-european-pharmacopoeia-cep